“We continued to execute well this quarter. Our VIKTORIA-1 study remains on-track, and we dosed the first patient in our Phase 1b/2 trial in metastatic castration resistant prostate cancer,” said Brian Sullivan, Celcuity’s Chief Executive Officer and co-founder. “With the addition of a Chief Commercial Officer to our executive team, we began the foundational work needed to prepare for the potential commercial launch of gedatolisib. We look forward to presenting topline data from the PIK3CA wild type patient sub-group later this year.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CELC:
- Celcuity Inc. Reports First Quarter Financial Results and Provides Corporate Update
- Celcuity Shareholders Approve Stock Plan Expansion and Elect Board
- Is CELC a Buy, Before Earnings?
- Celcuity Inc. Schedules Release of First Quarter 2024 Financial Results and Webcast/Conference Call
- Celcuity To Present at Upcoming Needham and Stifel Investor Conferences